FDA approves giredestrant for breast cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves giredestrant for breast cancer

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

  • 1

    The FDA approved giredestrant with everolimus for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer after specified prior endocrine therapy.

  • 2

    The FDA authorized FoundationOne Liquid CDx as a companion diagnostic to identify patients with ESR1 mutations.

  • 3

    In the phase 3 evERA trial, median progression-free survival among patients with ESR1-mutated tumors was 10 months with giredestrant plus everolimus and 5.5 months with comparator endocrine therapy pl

  • 4

    Objective response rates in patients with ESR1-mutated tumors were 27% with giredestrant plus everolimus and 14% with comparator endocrine therapy plus everolimus; overall survival data were immature.

  • 5

    Common adverse reactions included stomatitis, rash, fatigue, diarrhea, musculoskeletal pain, pneumonitis, and nausea; the prescribing information warns of bradycardia and embryo-fetal toxicity.

Original Source(s)

Related Content